Dr. Paz is an experienced executive in the biotech and pharma space, with demonstrated leadership and expertise in precision medecine, preclinical and clinical drug development and business development. She possesses profound, applicable scientific know-how of molecular and cellular biology, biochemistry, immunology, pharmacology, CMC, regulatory and clinical trial design. Dr. Paz is currently the Chief Development Officer at Nectin Therapeutics. Prior to that she held various leadership roles in biopharma companies, including ImClone Systems, Eli Lilly, Champions Oncology, Fortress Biotech and Stelexis Therapeutics. Keren holds a PhD from The Weizmann Institute of Science in Israel and was trained at The Rockefeller University and MSKCC under the mentoring of world-renowned scientists and Nobel laureates.

Mary Mader is a medicinal chemist whose career has spanned pharmaceutical, biotech and not-for-profit drug discovery. She contributed to the development of multiple clinical candidates for oncology indications at Eli Lilly and Company and Relay Therapeutics, focused on kinase and epigenetic targets. She served as chair of the medicinal chemistry Gordon Research Conference (2010), the inaugural medicinal chemistry Gordon Research Seminar (2013), the Chemistry in Cancer Research working group of the AACR (2023-2024), and the Expert Scientific Advisory Committee of the Medicines for Malaria Venture (2023-2028) and is on the editorial board of Molecular Cancer Therapeutics. She received her PhD from the University of Notre Dame in organic chemistry and completed an NIH post-doctoral fellowship at the University of California, Berkeley.

Andrew koff is the Head of the Laboratory of Cell Cycle Regulation
Sloan-Kettering Institute. He also serves as a professor at the Molecular Biology Program of Weill Cornell Medical College. His laboratory is interested in the mechanisms that control the decision of mammalian cells to either commit to the mitotic proliferative cycle or exit the cell cycle and differentiate, and the effect that mis-regulation of this decision has on development of a tissue and on tumor growth

Neal Rosen MD, PhD is a member of the Program in Molecular Pharmacology and the Department of Medicine at Memorial Sloan-Kettering Cancer Center where he also is the incumbent of the Enid Haupt Chair in Medical Oncology. He has pioneered the ideas that oncogene-induced negative feedback plays important roles in determining mechanisms of tumorigenesis and progression and that its relief causes adaptive resistance to targeted therapies. He has also played important roles in developing therapeutic strategies for inhibition of RAS/RAF/MEK or PI3K/mTOR signaling.

Dr. Shapiro received his PhD in 1987 and his MD in 1988 from Cornell University, followed by postgraduate training in internal medicine at Beth Israel Hospital, Boston, where he served as chief medical resident. He completed a fellowship in medical oncology at Dana-Farber Cancer Institute, during which he investigated the role of cell-cycle-related proteins in lung cancer. Dr. Shapiro’s practice is focused in the Center for Cancer Therapeutic Innovation, where he develops and leads early phase clinical trials. As Senior Vice President, Developmental Therapeutics, he also works integrally with multiple disease groups within the Institute.

Daniel Heller is the head of the Cancer Nanomedicine Laboratory at Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College. His laboratory develops nanotechnologies for the research, diagnosis, and treatment of cancer and allied diseases.

Dr. Schwartz is a board-certified medical oncologist, chief of Columbia University Medical Center’s Division of Hematology and Oncology and Deputy Director of the Herbert Irving Comprehensive Cancer Center. He is actively involved in translational and clinical research. His research studies have been supported by the National Cancer Institute, the Lustgarten Foundation for Pancreatic Cancer, the Department of Defense for Breast Cancer Research, the Byrne Foundation, and the Food and Drug Administration. He has served on the editorial boards of various scientific journals, including Associate Editor for the Journal of Clinical Oncology and Clinical Cancer Research. He is also actively involved in cooperative group activities and serves on the Board of Directors and Executive Committee of the Alliance for Clinical Trials in Oncology and is co-Chair of the Experimental Therapeutics Committee for Rare Cancers.

Dr. Simon Eastman received a BSc Honours degree in Biochemistry from Carleton University in 1986. His post-graduate studies were performed in the laboratory of Dr. Pieter Cullis at the University of British Columbia where he studied lipid asymmetry in model membranes and received his Ph.D. in 1991. His post-doctoral studies were undertaken in the laboratory of Dr. Ben de Kruijff at the University of Utrecht in the Netherlands.
From 1992 to 2002, Dr. Eastman worked as a research scientist at Genzyme Corporation in Framingham Massachusetts. There, he was involved in the development of non-viral gene therapy formulations. His work focused on developing an aerosolized formulation of cationic lipid:plasmid DNA to transfect the lungs of Cystic Fibrosis patients with a plasmid encoding for the cystic fibrosis transmembrane regulator (CFTR). This work led to the first clinical trial with an aerosolized non-viral gene therapy vector to the lungs of CF patients.
In 2002 Dr. Eastman moved to Northern Lipids Inc (now Evonik) where he was the Director of Formulation Development. NLI was a small CRO/CMO focused on the development of liposomal formulations of small molecules and macromolecules (proteins and nucleic acid based therapies). He directed scientific studies from early-stage programs through to scale up and technology transfer of processes to GMP facilities, both internally at NLI as well as to external CMO’s. At NLI Dr. Eastman participated in the design of facilities and custom equipment to allow for the safe manufacture of formulations containing potent API’s and for developing novel processes for the manufacture of numerous formulations (e,g. mixing equipment for the production of genetic material with lipids to form lipid nanoparticles).
From December of 2014 until July 2023, Dr. Eastman was Vice President of Global Manufacturing and Technical Operations at ProNai Therapeutics (subsequently Sierra Oncology). He was responsible for overseeing the manufacturing of Drug Substance and Drug Product, development of a secure supply chain, and overseeing analytical programs including development, qualification and validation. Sierra Oncology was acquired by GSK in July of 2022, following the filing of an NDA for Momelotinib which was approved in June of 2023. Dr. Eastman was retained by GSK until July 2023 to support tech transfer and participate in regulatory fillings (MAA and JP filings).